<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Ecnoglutide clinical trial &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/ecnoglutide-clinical-trial/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 07 Jan 2026 20:26:56 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Ecnoglutide clinical trial &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>cAMP-Biased GLP-1 Drug Ecnoglutide Excels in Diabetes Trial</title>
		<link>https://bioengineer.org/camp-biased-glp-1-drug-ecnoglutide-excels-in-diabetes-trial/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 07 Jan 2026 20:26:34 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cAMP-Biased GLP-1 analogue]]></category>
		<category><![CDATA[Ecnoglutide clinical trial]]></category>
		<category><![CDATA[GLP-1 receptor agonist therapy]]></category>
		<category><![CDATA[Glycemic control innovation]]></category>
		<category><![CDATA[type 2 diabetes treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/camp-biased-glp-1-drug-ecnoglutide-excels-in-diabetes-trial/</guid>

					<description><![CDATA[In a groundbreaking development poised to reshape the therapeutic landscape for type 2 diabetes, a recent multicentre phase 3 clinical trial has evaluated the safety and efficacy of ecnoglutide, a novel cAMP signalling-biased GLP-1 analogue. This study, rigorously designed as a randomised, double-blind, placebo-controlled investigation, provides compelling evidence that ecnoglutide monotherapy could emerge as a [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">314600</post-id>	</item>
	</channel>
</rss>
